MonumenTAL-6

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Jan 8, 2024 → Oct 29, 2026

Cited window

Jan 8, 2024 → Oct 29, 2026

Retrieved

Oct 31, 2026

Title

64407564MMY3009: A Phase 3 Randomized Study Comparing Talquetamab in Combination With Pomalidomide (Tal-P), Talquetamab in Combination With Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pom

Registry

NCT06208150

Study IDs

64407564MMY3009 · 2022-502446-27-00 (EUCT number)

Sponsor

Janssen Research & Development, LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Active, not recruiting

Enrollment

838 actual

Registered

2024-01-17

Start

2024-01-22 actual

Primary completion

2026-04-01 actual

Primary endpoint

Progression Free Survival (PFS)

Interventions

6 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –2 cited commentary passages leave a source question open, such as who was speaking. The report attributes no further than the source shows.
• –Not yet captured in this edition: a view on one-time cellular therapy versus continuous bispecific treatment and their quality-of-life trade-offs in relapsed myeloma.
• –Not yet captured in this edition: a view on strict infection precautions qualifying the practical accessibility of bispecific treatment in early-relapse myeloma.
• –Not yet captured in this edition: a view on belantamab alternatives when eligibility, infection risk or access limits T-cell-directed treatment in early relapsed myeloma.
• –Not yet captured in this edition: a view on multi-antigen targeting in later-line myeloma and uncertainty about durability, resistance prevention and cure.
• –Not yet captured in this edition: a remark on separately presented evidence for one-time cellular therapy versus continuous bispecific treatment in relapsed or refractory myeloma.
• –Not yet captured in this edition: a view on strict infection precautions despite the feasibility of delivering bispecific treatment in any center, including early relapse.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –257 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
• –The sources reviewed for this edition are not a representative sample of all HCP opinion. Searches emphasized the trial identifier and recognized names, so discussion that never named the trial, used different terminology or appeared outside those searches may be missing. Some potentially relevant passages were not fully assessed; absence from this report should not be read as absence of a view.
• –No full publication for NCT06208150 was discovered, and no protocol document was available from ClinicalTrials.gov. The July 2026 topline discussion described a first interim analysis without a congress presentation, trial-specific safety detail or disclosed data cutoff at that time. The released OS estimate lacked a confidence interval and p-value in that account. These limits constrain interpretation of both enthusiasm and adoption concerns.
• –Statements span different interviews, posts, development stages and clinical settings. An account of ongoing recruitment, completed accrual, anticipated results or future approval describes that source’s setting; dates alone do not establish a change of mind or disagreement.
• –MonumenTAL-2, RedirecTT-1, MonumenTAL-3, MajesTEC-3, MajesTEC-9 and CAR T studies inform the discussion but are not MonumenTAL-6 results. Their populations, regimens, dosing, follow-up and comparators differ. Informal comparisons and sequencing observations do not establish head-to-head superiority or an optimal sequence.
• –Some spoken numerical accounts remain ambiguous or inconsistent. These include a high-risk control estimate, a 12-month PFS description in the ReDIRECT TT1 discussion, comparator labels differing from the registered EPd/PVd comparison, and an account of death-risk reduction that differs from the OS HR reported elsewhere. The report preserves those accounts as attributed statements rather than reconciling them into new estimates.
• –Reposts, quoted posts, press-release summaries and media digests are not additional independent clinical endorsements. Organizations and automated accounts are distinguished from HCPs, and another party’s findings or opinion remain attributed to that party when relayed.
• –Four speakers are described in the sources as involved in MonumenTAL-6. Their statements are not treated as independent external assessments or given additional evidentiary weight because of that involvement.
• –Several discussion passages cannot be assigned to a named speaker. Their views remain attributed to the episode or discussion, without assuming that they represent a new participant, a separate endorsement or disagreement with another person in that source.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Some passages describe personal treatment experience or relay an unnamed oncologist’s reasoning. They provide patient-support and treatment-decision context, not separately identified direct HCP testimony or comparative outcome evidence.
• –Toxicity assessments are not uniform. Some accounts emphasize improvement with dose modification or holds, while others emphasize persistent symptoms or events unresolved at a study cutoff. Different studies, follow-up and individual experiences should not be collapsed into either universal reversibility or permanent irreversibility.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "MonumenTAL-6" (NCT06208150), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "monumental-6-06208150". If you cannot make requests, read https://www.erudio.com/reports/monumental-6-nct06208150.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT06208150", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct06208150 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/monumental-6-nct06208150.json
curl https://www.erudio.com/reports/monumental-6-nct06208150.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "monumental-6-06208150" })